RegulationPriority Review (United States), Breakthrough Therapy (United States), Priority Review (China), Promising Innovative Medicine (United Kingdom)

Structure/Sequence

Molecular FormulaC14H21N5O2S

InChIKeyIUEWXNHSKRWHDY-PHIMTYICSA-N

CAS Registry1622902-68-4

Clinical Trials associated with Abrocitinib

NCT07448363

/ Not yet recruitingNot ApplicableIIT

National Registry of Patients With Atopic Dermatitis Under Treatment With Dupilumab and JAK Inhibitors Within the Costa Rican Social Security System

The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:
What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?
What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?
Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.

Start Date01 May 2026

Sponsor / Collaborator-

NCT06899204

/ RecruitingNot Applicable

A Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis

This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the United States.
The aim of this study is to measure the effectiveness of abrocitinib in a real-world setting in patients with moderate-to-severe atopic dermatitis, with inadequate response or intolerance to ≤2 biologic therapies.

Start Date13 Jan 2026

Sponsor / Collaborator

Pfizer Inc.

NCT07242638

/ RecruitingPhase 2IIT

Use of Specific JAK Inhibition on Inflammatory Skin and Scalp Diseases in Down Syndrome R61AR084210

This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achieving Eczema Area and Severity Index (EASI) 75 response for AD, or SALT <= 20 for AA) will be kept on this dose, and non-responders based on these definitions, will initiate 200 mg daily for another 12 weeks. All AD and AA patients will be maintained on the respective dose of Abrocitinib from Week 24 through week 60.

Start Date12 Jan 2026

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

100 Clinical Results associated with Abrocitinib

100 Translational Medicine associated with Abrocitinib

100 Patents (Medical) associated with Abrocitinib

530

Literatures (Medical) associated with Abrocitinib

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort

Article

Author: Ulutaş Demirbaş, Gözde ; Esen, Mustafa ; Diremsizoglu, Esin ; Demirbaş, Abdullah

BACKGROUND:

Dose-stratified real-world data for JAK1 inhibitors in AD are limited.

OBJECTIVE:

To compare effectiveness and safety of standard vs high doses of abrocitinib and upadacitinib in routine care.

METHODS:

Multicenter, retrospective cohort study. The primary endpoint was Week-12 achievement of Eczema Area and Severity Index (EASI)-75. Secondary outcomes included patient-reported improvements at Minimal Clinically Important Difference (MCID) thresholds, Minimal Disease Activity (MDA) at Week 36, time-to-EASI-75, and treatment-emergent adverse events(TEAE).

RESULTS:

A total of 124 patients were analyzed (abrocitinib 100 mg, n = 28; abrocitinib 200 mg, n = 32; upadacitinib 15 mg, n = 30; upadacitinib 30 mg, n = 34). At Week 12, EASI-75 was achieved in 20/32 (62.5%) versus 10/28 (35.7%) for abrocitinib (OR 2.94, 95% CI 1.06-8.15; p = 0.036) and in 22/34 (64.7%) versus 14/30 (46.7%) for upadacitinib (OR 2.92, 95% CI 1.16-7.38; p = 0.021), favoring the higher-dose regimens. Itch improvement was more frequent with higher doses. By Week 36, full minimal disease activity was observed in 30.2% of patients receiving abrocitinib 200 mg and 26.7% receiving upadacitinib 30 mg, compared with 18.4% and 20.0% in the lower-dose groups. Kaplan-Meier analysis showed faster responses with high doses (median 12 vs 36 weeks; log-rank p < 0.01). Safety was comparable across groups.

CONCLUSION:

High-dose JAK1 regimens achieve faster, numerically greater disease control without short-term safety tradeoffs, supporting escalation in suboptimal responders.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost-utility and budget impact analysis of dupilumab and oral Janus kinase (JAK) inhibitors for treating moderate-to-severe atopic dermatitis in Taiwan

Article

Author: Lee, John Tayu ; Wu, David Bin-Chia ; Shen, Toby Kai-Bo ; Yang, Rachel Ai-Ting ; Tan, Hsiao-Hsiao ; Liu, Valerie Tzu-Ning ; Wang, Yen Hsiang

BACKGOROUND:

Atopic dermatitis (AD), a chronic inflammatory skin disease, affects 1.28% of Taiwan's population, with 26.69% having moderate-to-severe cases, causing significant healthcare costs and quality-of-life impairments. Conventional treatments often fail these patients, necessitating novel therapies like dupilumab and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib). This study evaluates the cost-utility and budget impact of these therapies versus best supportive care (BSC) for adults with moderate-to-severe AD from Taiwan's NHI perspective.

METHODS:

A hybrid decision tree-Markov model assessed short- and long-term (Years 1-20) outcomes using trial efficacy, NHI costs (2022 NT$), and EQ-5D utilities. Interventions included topical corticosteroids/calcineurin inhibitors. Outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs), discounted at 3%, with a NT$2,000,000/QALY threshold. Sensitivity analyses tested robustness. A five-year (2026-2030) budget impact analysis (BIA) included epidemiology and market uptake.

RESULTS:

Upadacitinib 30 mg was most cost-effective (11.0782 QALYs, ICER NT$1,250,903/QALY vs BSC), followed by Upadacitinib 15 mg (NT$1,376,435/QALY). Dupilumab was dominated; Baricitinib's ICERs exceeded NT$2,000,000/QALY. Sensitivity analyses confirmed robustness, with utility gains, medication costs, and discontinuation rates as key drivers. The BIA estimated a NT$117 billion incremental impact, driven by drug costs, with per-patient increments falling from NT$339,769 to NT$264,728.

CONCLUSION:

Upadacitinib 30 mg was the most cost-effective option for moderate-to-severe atopic dermatitis in Taiwan, but its high budget impact underscores the need for strategic pricing and reimbursement policies to ensure long-term affordability and access.

02 Mar 2026·Dermatitis

Decision-Making Factors for Systemic Therapies in Atopic Dermatitis: A Clinical Review.

Review

Author: Mehta, Apoorva ; Guttman-Yassky, Emma ; O'Hagan, Ross ; Lamb, Angela J ; Levine, Jasmine

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impairs quality of life. In recent years, treatment has advanced from broad immunosuppressants to targeted biologics and small-molecule therapies that modulate type 2 inflammation and itch signaling. Dupilumab, tralokinumab, lebrikizumab, and nemolizumab are now FDA-approved biologics with demonstrated efficacy and favorable long-term safety, while oral Janus kinase inhibitors (JAKis) such as abrocitinib, upadacitinib, and baricitinib often provide rapid disease control but carry black-box warnings. Comparative trials highlight faster itch relief with JAKis but durable disease control and safety advantages with biologics. The expanding treatment landscape necessitates individualized therapy selection. Key clinical considerations include patient age, pregnancy status, infection, malignancy, or thromboembolic risk, comorbid conditions, and history of adverse effects. Equally important are patient-centered preferences such as dosing frequency, route of administration, storage logistics, and willingness to self-inject. Access and affordability also influence care, with many manufacturers offering copay support and patient assistance programs. Future directions emphasize head-to-head comparative studies, biomarker development for precision treatment, and equitable access to advanced therapies. This narrative review synthesizes current evidence on biologics and JAKis in AD, outlining efficacy, safety, and practical decision-making factors to guide dermatologists in aligning therapies with both clinical context and patient priorities.

News (Medical) associated with Abrocitinib

30 Mar 2026
·allsci.com

Sanofi’s amlitelimab meets Phase III endpoints in atopic dermatitis with extended 12-week dosing interval

Sanofi (NASDAQ: SNY) reported Phase III data from three trials of amlitelimab in moderate-to-severe atopic dermatitis, showing that the anti-OX40L antibody met primary endpoints across monotherapy and combination settings — with efficacy at a dosing interval of once every 12 weeks that matched the every-four-week regimen. The results, presented as late-breaking research at the 2026 American Academy of Dermatology annual meeting in Denver, position amlitelimab as a mechanistically distinct entrant into a treatment landscape that has grown crowded but remains defined by frequent dosing and incomplete responses. The COAST 1 and COAST 2 trials were randomized, double-blind, placebo-controlled Phase III studies evaluating amlitelimab monotherapy in adults and adolescents aged 12 and older with moderate-to-severe atopic dermatitis. SHORE used the same design but tested amlitelimab in combination with topical corticosteroids, with or without topical calcineurin inhibitors. Across the three trials, 1,786 patients were enrolled at sites spanning North America, Europe, Asia, and Latin America. The primary endpoint for all three studies was the proportion of patients achieving a validated Investigator Global Assessment for atopic dermatitis (vIGA-AD) score of 0 or 1 — clear or almost clear skin — with at least a two-point reduction from baseline at Week 24. Both the Q4W and Q12W amlitelimab arms met this endpoint in each trial.For US and US reference countries, the primary endpoint was vIGA-AD 0/1 with a ≥2-point reduction. Of note, for the EU reference countries and Japan, the studies used co-primary endpoints that included the same vIGA-AD measure plus EASI-75. In COAST 1, vIGA-AD 0/1 rates were 21.1% (Q4W) and 22.5% (Q12W) versus 9.2% for placebo. EASI-75 — the proportion of patients achieving at least 75% improvement in the Eczema Area and Severity Index — reached 35.9% and 39.1% in the Q4W and Q12W arms, respectively, compared to 19.1% for placebo. Itch reduction, measured by a four-point or greater decrease in peak pruritus numerical rating scale, was 22.5% (Q4W) and 24.5% (Q12W) versus 12.7% for placebo. All key secondary endpoints in COAST 1 reached statistical significance. COAST 2 showed a similar pattern, with vIGA-AD 0/1 rates of 25.3% (Q4W) and 25.7% (Q12W) versus 14.8% for placebo. EASI-75 and itch endpoints reached nominal significance, though one secondary endpoint — vIGA-AD 0/1 with barely perceptible erythema — did not achieve statistical significance. The distinction between the two monotherapy trials is worth noting: COAST 2’s higher placebo response rate narrowed the treatment delta, a common challenge in atopic dermatitis trials with geographically diverse enrollment. SHORE, the combination study, produced the highest absolute response rates. vIGA-AD 0/1 was achieved by 28.7% (Q4W) and 32.3% (Q12W) of patients versus 16.8% on placebo plus topical therapy alone. EASI-75 reached 48.1% and 46.8% in the active arms versus 32.3% for placebo. All primary and key secondary endpoints were statistically significant. Across all three trials, Sanofi reported that efficacy was progressively increasing at Week 24 with no evidence of plateau, suggesting that longer treatment durations may yield higher response rates — a pattern that will be tested in the ongoing ESTUARY extension study. The safety profile was consistent with earlier-phase data. The most common adverse events across COAST 1, COAST 2, and SHORE were nasopharyngitis, atopic dermatitis flares, and upper respiratory tract infections, occurring at rates generally comparable to or lower than placebo. Malignancy rates were below 1% and similar between active and placebo groups. No severe injection site reactions or serious gastrointestinal ulceration events were reported. Sanofi disclosed a second case of Kaposi’s sarcoma in the amlitelimab development program, identified in the still-blinded ESTUARY Phase III extension study. Both Kaposi’s sarcoma cases occurred in patients with known risk factors, and both patients discontinued treatment and entered recovery. Out of an estimated 3,778 patients exposed to amlitelimab across all indications, no additional cases have been identified. The signal remains numerically small but warrants monitoring given the immunomodulatory mechanism. Sanofi stated that it “believes that amlitelimab continues to have the potential to be a meaningful and convenient option for patients with AD”. Amlitelimab is a fully human, non-T cell depleting monoclonal antibody that blocks OX40 ligand, a costimulatory molecule involved in the activation and survival of effector T cells. By targeting this upstream pathway, the drug aims to modulate pathogenic immune responses without the broad immunosuppression associated with JAK inhibitors or the cytokine-specific blockade of IL-4/IL-13 antibodies. The non-depleting design distinguishes it from therapies that reduce T cell populations, potentially offering a different safety-efficacy tradeoff. The atopic dermatitis treatment landscape in 2026 includes six approved systemic therapies for moderate-to-severe disease: dupilumab and tralokinumab (both anti-IL-4/IL-13 pathway), lebrikizumab (anti-IL-13), nemolizumab (anti-IL-31 receptor), and the oral JAK1 inhibitors abrocitinib and upadacitinib. All approved injectable biologics require dosing every two to four weeks. Amlitelimab’s Q12W regimen — approximately four injections per year — would represent a substantial reduction in treatment burden if the dosing schedule is maintained in regulatory filings. Cross-trial comparisons are limited by differences in study populations, placebo rates, and endpoint definitions, but the absolute vIGA-AD 0/1 and EASI-75 rates observed in the COAST and SHORE trials are numerically lower than those reported for dupilumab and upadacitinib in their respective pivotal programs. Whether the dosing convenience and mechanistic novelty offset the apparent efficacy gap will be a central question for regulators, payers, and prescribers. Rocatinlimab, developed by Amgen, targets the OX40 receptor rather than the ligand and is also in Phase III development for atopic dermatitis. The two drugs represent competing approaches to the same pathway, and their relative clinical profiles will become clearer as more data emerge. A 2024 review in the Journal of Dermatology and Therapy examined both molecules, noting that while they share a pathway target, their binding sites and downstream effects may differ. Results from ESTUARY, evaluating Q12W maintenance dosing and longer-term safety, are anticipated in the second half of 2026. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultPhase 3Immunotherapy

27 Mar 2026
·allsci.com

Almirall, Lilly’s Ebglyss maintains skin clearance for up to four years in atopic dermatitis

Almirall (BME: ALM) presented interim data from the Phase IIIb ADlong study showing that lebrikizumab maintained skin clearance and itch control for up to four years in patients with moderate-to-severe atopic dermatitis, extending the durability evidence for the IL-13 inhibitor marketed under the trade name Ebglyss. The findings, disclosed at the American Academy of Dermatology Annual Meeting in Denver on March 27, 2026, add to a growing body of long-term data in a therapeutic class where sustained disease control remains a central question for clinicians and payers. Almirall is partnered on lebrikizumab’s global development with Eli Lilly. ADlong Phase IIIb results ADlong is an open-label extension study evaluating lebrikizumab 250 mg every four weeks in adults and adolescents with moderate-to-severe atopic dermatitis. The interim analysis included 174 patients who had completed prior lebrikizumab trials, representing up to four years of continuous treatment. At week 48, 94% of patients achieved EASI-75, 75% reached EASI-90, and 68% achieved an Investigator’s Global Assessment score of 0 or 1. Seventy-eight percent reported meaningful itch reduction. Most patients were maintained on monotherapy without topical corticosteroids. The responder-enriched design and observed-case analysis may overestimate efficacy, as only patients who completed earlier studies were included. Safety was consistent with prior studies, with mainly mild to moderate adverse events and no new safety signals reported. The development context for lebrikizumab Lebrikizumab is a monoclonal antibody that binds IL-13, a type 2 cytokine that drives skin barrier dysfunction, inflammation, and pruritus in atopic dermatitis. By blocking IL-13 from engaging its receptor complex, lebrikizumab inhibits downstream signaling without broader immunosuppression. This selective mechanism distinguishes it from dupilumab (Dupixent, Sanofi/Regeneron), which blocks both IL-4 and IL-13 through the IL-4 receptor alpha subunit, and from oral JAK inhibitors such as upadacitinib (Rinvoq, AbbVie) and abrocitinib (Cibinqo, Pfizer), which act on intracellular kinase pathways. The atopic dermatitis biologic market is anchored by dupilumab, first approved in 2017, with extensive real-world and long-term extension data. Tralokinumab (Adtralza/Adbry, LEO Pharma), the other approved IL-13 inhibitor, was authorized in 2021. Lebrikizumab gained approval in both Europe and the US in 2024, with Eli Lilly retaining development and commercialization rights outside Europe. The EASI-75 rate of 94% reported in ADlong appears numerically higher than long-term extension data reported for dupilumab and tralokinumab in similar open-label settings. However, cross-trial comparisons are limited by differences in study design, patient selection, duration, and analytical methods. The ADlong population’s enrichment for prior responders makes direct comparison to other extension studies particularly difficult. No head-to-head trials between lebrikizumab and dupilumab or tralokinumab have reported results. The oral JAK inhibitors occupy a different position in the treatment algorithm, generally reserved for patients who have not responded to or cannot tolerate biologics, partly due to safety considerations including cardiovascular and thromboembolic risks associated with the JAK class. The ADlong study is ongoing and will continue for an additional year of treatment, with further data expected to clarify the durability of response and long-term safety. Almirall and Eli Lilly are also conducting Phase III trials in related indications, including perennial allergic rhinitis (NCT06339008) and chronic rhinosinusitis with nasal polyps (NCT06338995), as well as additional atopic dermatitis studies. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultPhase 3Drug Approval

23 Mar 2026
·allsci.com

Apogee’s IL-13 zumilokibart shows durable responses in atopic dermatitis with 3-, 6-month dosing

Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotech based in San Francisco and Boston, reported 52-week maintenance data from the Phase II APEX Part A trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis, with results showing that patients maintained and deepened clinical responses on dosing schedules of every three or six months. If confirmed in placebo-controlled and Phase III studies, the zumilokibart atopic dermatitis data could position the anti-IL-13 antibody as a less frequently dosed alternative to current biologics that require injections as often as every two weeks. Trial specifics The APEX trial is a Phase II study evaluating zumilokibart at 360mg administered subcutaneously at three- and six-month intervals in adults with moderate-to-severe atopic dermatitis. Part A assessed maintenance of response over 52 weeks among patients who had completed a 16-week induction period. Among patients who achieved response at Week 16, 75% and 85% maintained EASI-75 — a 75% or greater reduction in the Eczema Area and Severity Index — with every three-month and every six-month dosing, respectively. Maintenance of clear or almost clear skin, measured by validated Investigator’s Global Assessment (vIGA) scores of 0 or 1, was observed in 86% of patients on three-month dosing and 78% on six-month dosing. The company also reported that deepening of response occurred across all lesional and itch endpoints in the full population of patients initially randomized to zumilokibart, not solely among Week 16 responders. The EASI-75 zumilokibart results, together with the vIGA data, form the core of the efficacy case the company is building ahead of Phase III. Zumilokibart was well tolerated across both dosing regimens over the full 52-week study period. The most common treatment-emergent adverse events were noninfective conjunctivitis, upper respiratory tract infection, and nasopharyngitis — a profile the company described as generally consistent with other agents in the IL-13 inhibitor class. Mechanism and drug context Zumilokibart is a subcutaneous monoclonal antibody engineered with an extended half-life that targets interleukin-13, a cytokine considered a primary driver of the inflammation, barrier dysfunction, and pruritus characteristic of atopic dermatitis. According to the company, zumilokibart achieves greater than 99% inhibition of IL-13, which Apogee Therapeutics argues underpins the rapid onset and sustained depth of response observed in the APEX trial atopic dermatitis data. The extended half-life engineering is what enables the three- and six-month dosing intervals that distinguish the Apogee Therapeutics APG777 program from existing biologics in the class. The moderate-to-severe atopic dermatitis treatment landscape has expanded in recent years with the approval of dupilumab (Dupixent), an anti-IL-4 receptor alpha antibody administered every two weeks; tralokinumab (Adbry), an anti-IL-13 antibody dosed every two weeks during induction and every two to four weeks thereafter; and oral JAK inhibitors including upadacitinib (Rinvoq) and abrocitinib (Cibinqo). Dupilumab remains the most widely prescribed biologic in the indication. Tralokinumab is the most direct comparator for zumilokibart given their shared IL-13 target. In its pivotal trials, tralokinumab demonstrated EASI-75 rates of approximately 25–33% at Week 16 versus placebo rates of around 10–13%, with maintenance dosing every two weeks or every four weeks. The zumilokibart maintenance data — showing 75–85% of Week 16 responders maintaining EASI-75 at 52 weeks on three- or six-month dosing — appear numerically distinct in terms of dosing frequency, though cross-trial comparisons are limited by differences in study design, patient populations, and the absence of a placebo arm in the APEX Part A maintenance phase. The Part A data represent a responder-enriched population, which inflates absolute response rates relative to intent-to-treat analyses from pivotal trials. The dosing interval is the central differentiator. Current standard-of-care biologics require between 13 and 26 injections per year. If zumilokibart’s efficacy and safety are confirmed in controlled studies, a regimen of two to four doses per year would represent a meaningful reduction in treatment burden. Whether this translates into improved adherence and real-world outcomes remains to be determined. What next for the APEX trial APEX Part B, a placebo-controlled dose optimization segment that randomized 347 patients 1:1:1:1 to high-, medium-, or low-dose zumilokibart versus placebo, is expected to report 16-week induction data in the second quarter of 2026. That readout will provide the first controlled efficacy comparison for the molecule in atopic dermatitis and will be a more informative test of zumilokibart’s treatment effect size relative to placebo. Based on the Part A and anticipated Part B results, Apogee plans to initiate Phase III trials of zumilokibart in moderate-to-severe atopic dermatitis in the second half of 2026, with a potential commercial launch targeted for 2029. The 52-week data will be presented in a late-breaking oral presentation at the 2026 American Academy of Dermatology Annual Meeting on March 28 in Denver. The company has also disclosed plans to expand zumilokibart’s development into asthma, eosinophilic esophagitis, and other inflammatory and immunology indications, though timelines for those programs were not specified in the current disclosure. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultPhase 2Phase 3

100 Deals associated with Abrocitinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11400	Abrocitinib	D11AH	DB14973

R&D Status

Approved

10 top approved records.
Login
to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	United Kingdom	Pfizer Inc.	08 Sep 2021

Developing

10 top R&D records.
Login
to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Eczema	Phase 3	United States	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	China	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Argentina	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Belgium	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Brazil	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Bulgaria	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Canada	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Chile	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Germany	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Israel	Pfizer Inc.	11 Jun 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03422822 \| NCT03575871 \| NCT03349060 \| NCT03796676 \| NCT03627767 (JADE MONO-1, MONO-2, TEEN, REGIMEN, EXTEND, Pubmed \| Allergy)	Phase 3	Moderate Atopic Dermatitis	-	Abrocitinib 200mg	evsikfdrsw(vuenotznxd) = chudfyhzym xrbqyjbdef (zsnszfdshg ) View more	Positive	01 Aug 2025
				Abrocitinib 100mg	evsikfdrsw(vuenotznxd) = msgmxoduuc xrbqyjbdef (zsnszfdshg ) View more
AHEAD (NEWS) Manual	Not Applicable	Dermatitis, Atopic	-	阿布昔替尼 (未接受过其他系统治疗)	htevwstooj(zcvlerqvvg) = cerxbloegi oynzovumfb (nmtaxptcmi )	Positive	27 Jun 2025
				阿布昔替尼 (既往接受过系统治疗)	htevwstooj(zcvlerqvvg) = krwyuzcgph oynzovumfb (nmtaxptcmi )
ChiCTR2200063195 (Pubmed) Manual	Not Applicable	Dermatitis, Atopic	117	Abrocitinib	icojuknwiw(vkzwqnwwvc) = wptyhmkypm vwnksbcuzl (bqprdugaur ) View more	Positive	01 May 2025
NCT03349060 (JADE MONO-1, AAD2025)	Phase 3	Dermatitis, Atopic	-	Abrocitinib 200 mg	vuqgqtblgc(vwnxkvldty) = vnbjinsumb umncgropng (tlhzjysbaa ) View more	Positive	07 Mar 2025
				Abrocitinib 100 mg	vuqgqtblgc(vwnxkvldty) = yohzbszitz umncgropng (tlhzjysbaa ) View more
NCT03422822 (JADE EXTEND, AAD2025)	Phase 3	Alopecia Areata \| Dermatitis, Atopic	71	Abrocitinib 200 mg	vcoggjnhye(tbcjmghcvq) = 2 patients (31-year-old White male [previously reported] and 38-year-old White male) treated with consistent-dose abrocitinib 200 mg and 2 patients (42- and 49-year-old White males) in the variable-dose cohort reported an AE of hair growth/regrowth. Greater proportions of patients treated with consistent-dose abrocitinib 200 mg versus 100 mg achieved Week 12 IGA 0/1 (44% [11/25] vs 25% [3/12]), EASI-75 (61% [19/31] vs 25% [3/12]), and PP-NRS4 (56% [15/27] vs 22% [2/9]). Abrocitinib improved itch and skin clearance in substantial proportions of patients with AD and comorbid AA; hair growth/regrowth was reported in 4 patients. bpwvdeukzi (awseulhukw )	Positive	07 Mar 2025
				Abrocitinib 100 mg
NCT03349060 (JADE MONO-1, AAD2025)	Phase 3	Dermatitis, Atopic	2,082	Abrocitinib 100 mg	thnuefodla(hxjynvqiso) = misjvvmmlj ayhfokzhmg (gclhrgnzni ) View more	Positive	07 Mar 2025
				Abrocitinib 200 mg	jvhrnlnbrg(tmgacikpjp) = zimmndriyj ovepzjknid (taozvzndrk ) View more
AAD2025	Not Applicable	Severe Atopic Dermatitis	530	Upadacitinib	zfrsfuarcf(rwepnlniam) = ehjxxuilpe foraefttia (umdbdatpfk ) View more	Positive	07 Mar 2025
				Baricitinib	zfrsfuarcf(rwepnlniam) = dmtcqjyvwr foraefttia (umdbdatpfk ) View more
AAD2025	Not Applicable	Dermatitis, Atopic	123	tralokinumab	ansplcwvge(nnisxagvjm) = upnpvhulxd bncbuxlcnv (wjyxknboyd ) View more	Positive	07 Mar 2025
				abrocitinib	ansplcwvge(nnisxagvjm) = vcqvmfgcyk bncbuxlcnv (wjyxknboyd ) View more
NCT04345367 (JADE DARE, AAD2025)	Phase 3	Moderate Atopic Dermatitis	727	Abrocitinib 200 mg	dtyytpggtf(gfaqkxifjo) = uyptamvrov josuvnrdym (pqzitxhmrh, 0.5 - 0.9)	Positive	07 Mar 2025
				Dupilumab 300 mg	dtyytpggtf(gfaqkxifjo) = zsrskpbpuy josuvnrdym (pqzitxhmrh, 0.2 - 0.7)
NCT05375929 (CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	200	Abrocitinib (Main Study: Abrocitinib 200 mg)	jugwendhqb = qkbxyijtkj ehrwwhgddp (hiippgemzt, gzamejrkav - nqsdmctrwa) View more	-	19 Sep 2024
				Abrocitinib (Main Study: Abrocitinib 100 mg)	jugwendhqb = ovejdqraqj ehrwwhgddp (hiippgemzt, ohwnvlicca - fcgukeqpji) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

view full example data

Deal

Boost your decision using our deal data.

login

view full example data

Core Patent

Boost your research with our Core Patent data.

login

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

login

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

login

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

view full example data

AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free

Abrocitinib

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation